Financial Results - OS Therapies Incorporated reported financial results for Q1 2025, ending March 31, 2025[5] - A press release detailing the financial results was issued on May 16, 2025[5] - The financial results include key metrics that will be detailed in the attached press release (Exhibit 99.1)[6] - The report does not provide specific financial figures or performance metrics in the current document[5] Company Classification and Focus - The company is classified as an emerging growth company under the Securities Act[3] - The company is focused on clinical-stage cancer immunotherapy and ADC biotechnology[5] Company Information - The company is headquartered in Grasonville, Maryland[2] - The trading symbol for OS Therapies Incorporated is OSTX, listed on NYSE American[2] Regulatory Compliance - The report is filed under Section 13 or 15(d) of the Securities Exchange Act of 1934[1] - The document is signed by Paul A. Romness, President and CEO, confirming the report's authenticity[13]
OS Therapies Incorporated(OSTX) - 2025 Q1 - Quarterly Results